Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 1/20 | 0.31 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.31 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.31 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.31 |
| ▸ | DCTPP1 | Q9H773 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20043393 | 0.83 | — | — | |
| SCHEMBL20043310 | 0.81 | BACE1 (0.31) | — | |
| SCHEMBL20043392 | 0.81 | — | — | |
| SCHEMBL20043315 | 0.79 | PIM2 (0.33) | CYP3A4CYP2C9CYP2C19 | |
| SCHEMBL15314157 | 0.78 | HTR3E (0.38) | CYP3A4CYP2D6CYP2C9CYP2C19DCTPP1 | |
| SCHEMBL20043319 | 0.77 | — | — | |
| SCHEMBL20043309 | 0.76 | MITF (0.34) | — | |
| SCHEMBL15314170 | 0.72 | CYP3A4 (0.35) | CYP3A4CYP2D6CYP2C9CYP2C19DCTPP1 | |
| SCHEMBL22769044 | 0.70 | — | — | |
| SCHEMBL17723012 | 0.69 | CYP3A4 (0.40) | CYP3A4CYP2D6CYP2C9CYP2C19DCTPP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11261200-B2 | Heteroaryltrifluoroborate compounds for the treatment of mycobacterial infections | THE GLOBAL ALLIANCE FOR TB DRUG DEVELOPMENT, INC. (US) | 2022-03-01 | — | — | US | disclosed |
| US-20190276478-A1 | HETEROARYLTRIFLUOROBORATE COMPOUNDS FOR THE TREATMENT OF MYCOBACTERIAL INFECTIONS | THE GLOBAL ALLIANCE FOR TB DRUG DEVELOPMENT, INC | 2019-09-12 | — | — | US | disclosed |
| US-20190276478-A1 | HETEROARYLTRIFLUOROBORATE COMPOUNDS FOR THE TREATMENT OF MYCOBACTERIAL INFECTIONS | THE GLOBAL ALLIANCE FOR TB DRUG DEVELOPMENT, INC | 2019-09-12 | — | — | US | disclosed |
| WO-2018067762-A2 | HETEROARYLTRIFLUOROBORATE COMPOUNDS FOR THE TREATMENT OF MYCOBACTERIAL INFECTIONS | THE GLOBAL ALLIANCE FOR TB DRUG DEVELOPMENT, INC. (US) | 2018-04-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11261200-B2 | Heteroaryltrifluoroborate compounds for the treatment of mycobacterial infections | FNTB, CYP2F1, SDHB | CYP3A4 99/4885CYP2D6 31/4885CYP2C9 139/4885 |
| US-20190276478-A1 | HETEROARYLTRIFLUOROBORATE COMPOUNDS FOR THE TREATMENT OF MYCOBACTERIAL INFECTIONS | FNTB, CYP2F1, SDHB | CYP3A4 99/4885CYP2D6 31/4885CYP2C9 139/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.